CN100339132C - 抗血栓剂 - Google Patents

抗血栓剂 Download PDF

Info

Publication number
CN100339132C
CN100339132C CNB008197237A CN00819723A CN100339132C CN 100339132 C CN100339132 C CN 100339132C CN B008197237 A CNB008197237 A CN B008197237A CN 00819723 A CN00819723 A CN 00819723A CN 100339132 C CN100339132 C CN 100339132C
Authority
CN
China
Prior art keywords
ser
gly
thr
seq
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008197237A
Other languages
English (en)
Chinese (zh)
Other versions
CN1501812A (zh
Inventor
弗兰克·C·巴龙
迈克尔·N·布莱克本
乔拉·Z·福伊尔斯坦
约翰·R·图米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1501812A publication Critical patent/CN1501812A/zh
Application granted granted Critical
Publication of CN100339132C publication Critical patent/CN100339132C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB008197237A 2000-05-15 2000-10-05 抗血栓剂 Expired - Fee Related CN100339132C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
US09/571,434 2000-05-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200710141110XA Division CN101134107A (zh) 2000-05-15 2000-10-05 抗血栓剂

Publications (2)

Publication Number Publication Date
CN1501812A CN1501812A (zh) 2004-06-02
CN100339132C true CN100339132C (zh) 2007-09-26

Family

ID=24283688

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200710141110XA Pending CN101134107A (zh) 2000-05-15 2000-10-05 抗血栓剂
CNB008197237A Expired - Fee Related CN100339132C (zh) 2000-05-15 2000-10-05 抗血栓剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA200710141110XA Pending CN101134107A (zh) 2000-05-15 2000-10-05 抗血栓剂

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1282444B1 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20030034071A (enExample)
CN (2) CN101134107A (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU2000278584B2 (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4485806B2 (ja) 2002-03-20 2010-06-23 ユニヴァーシティ オブ メリーランド，ボルチモア 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US7872048B2 (en) 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
US10583094B2 (en) * 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
LT3002298T (lt) * 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
EP3617316A4 (en) 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026010A1 (en) * 1996-01-17 1997-07-24 Smithkline Beecham Corporation Anticoagulant agents useful in treatment of thrombosis
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) * 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026010A1 (en) * 1996-01-17 1997-07-24 Smithkline Beecham Corporation Anticoagulant agents useful in treatment of thrombosis
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) * 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antithrombotic efficacy of a novel murine antihuman facto antibody in rats Feuerstein et al,Arterioscler Thromb Vasc Biol.,Vol.19 No.10 1999 *

Also Published As

Publication number Publication date
DE60032029D1 (de) 2007-01-04
NZ522632A (en) 2005-05-27
WO2001087339A1 (en) 2001-11-22
HUP0301804A3 (en) 2005-12-28
EP1282444B1 (en) 2006-11-22
HUP0301804A2 (hu) 2003-08-28
DE60032029T2 (de) 2007-05-31
US20050037006A1 (en) 2005-02-17
EP1825864A2 (en) 2007-08-29
AU7858400A (en) 2001-11-26
BR0015872A (pt) 2004-08-03
NO20025463D0 (no) 2002-11-14
KR20030034071A (ko) 2003-05-01
CN1501812A (zh) 2004-06-02
AU2000278584B2 (en) 2006-11-16
CN101134107A (zh) 2008-03-05
ES2277597T3 (es) 2007-07-16
EP1282444A1 (en) 2003-02-12
ZA200209265B (en) 2003-10-22
EP1282444A4 (en) 2004-06-30
MXPA02011385A (es) 2004-01-26
PL360060A1 (en) 2004-09-06
JP2004516236A (ja) 2004-06-03
HU225874B1 (en) 2007-11-28
CZ20023778A3 (cs) 2003-08-13
CA2411369A1 (en) 2001-11-22
ATE345816T1 (de) 2006-12-15
EP1825864A3 (en) 2007-09-12
KR20070116192A (ko) 2007-12-06
IL152831A0 (en) 2003-06-24
NO20025463L (no) 2003-01-09

Similar Documents

Publication Publication Date Title
CN1213312A (zh) 用于治疗血栓形成的抗凝血剂
RU2426741C2 (ru) Антагонистические антитела к il-17
CN100339132C (zh) 抗血栓剂
CN1303431A (zh) 抗人组织因子和人源化抗体以及人源化抗体的制作方法
CN1390258A (zh) 因子Ⅸ/因子lxa－抗体和抗体衍生物
CN1671417A (zh) 抗髓鞘相关糖蛋白(mag)抗体
CN1183160C (zh) 人抗因子IX/IXa抗体
CN1599624A (zh) 抑制血液凝固的抗体及其使用方法
CN1575302A (zh) 人组织因子抗体
AU2000278584A1 (en) Antithrombotic agents
US20040146511A1 (en) Antithrombotic agents
CN1230201C (zh) 血小板特异性的嵌合性免疫球蛋白及其使用方法
TW201825518A (zh) 新型抗-pcsk9抗體
TW201825524A (zh) 新型抗-pcsk9抗體
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
CA2243236A1 (en) Anticoagulant agents useful in treatment of thrombosis
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
HK1207559B (en) Il-17 antagonistic antibodies
HK1101277B (en) Il-17 antagonistic antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee